Products

Signal Tracker Data Platform Data Enrichment API Intelligence desk

Solutions

Inward Investment & Aftercare Deal Origination Executive Search Corporate Development Signal-Based Outbound Competitive Intelligence Funding Signals Competitor Monitoring For Sales Teams For Founders For Agencies For Investors

Explore

Companies Live Signals Markets Trends

Resources

Signal Checker Blog Integrations FAQ Contact Pricing
Login Book a demo
Corlieve Therapeutics logo — At Corlieve, we are focused on bringing novel therapeutic op...

Corlieve Therapeutics

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders.

Founded 2019 France France 1 employees Seed Biotechnology, Health Care

General Information

Company Name Corlieve Therapeutics
Founded Year 2019
Location France France +1
Employees 1
Industries Biotechnology, Health Care
Funding Stage Seed
Social

Get notified when Corlieve Therapeutics moves

Funding, new markets, leadership changes, hiring surges — one e-mail, only when something happens.

Free · no account needed

About Corlieve Therapeutics

Corlieve Therapeutics is a biotechnology company, established in 2019 in France. As a fully owned subsidiary of UniQure, the company is dedicated to offering innovative treatment options for individuals grappling with severe neurological conditions. The recent milestone for Corlieve Therapeutics was the Seed Round investment on 02 November 2020, which was facilitated by prominent investors including IDInvest Partners, Kurma Partners, Kinled Holding Ltd, and Pureos Bioventures. The company's focus on addressing critical unmet needs in the field of neurological disorders is echoed in their slogan, "At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders." This strategic objective aligns with the growing demand for innovative solutions in the Health Care sector. Corlieve Therapeutics' position as a subsidiary of UniQure also adds to its credibility, benefitting from the expertise and resources of an established biotechnology company. This recent investment indicates a vote of confidence from major players in the investment landscape and underlines the potential for Corlieve Therapeutics to make significant strides in the biotechnology industry.

Taxonomy: Neurological Disorders, Therapeutics, Drug Development, Clinical Research, Gene Therapy, Neuroscience, Innovative Medicine, Biopharmaceuticals

Funding Rounds & Investors (1)

View All
Funding Stage Amount Investors Lead Investors Date
Seed Round •••••• 4
Investor Investor Investor
•••• •••• 		02 Nov 2020

Latest News

View All
Kurma Partners raises €140 million first close of new €250 million Biofund IV — Eu-startups
Kurma Partners raises €140 million first close of new €250 million Biofund IV
Eu-startups Oct 03, 2024

FAQ About Corlieve Therapeutics

At Corlieve, we are focused on bringing novel therapeutic options to patients with severe neurological disorders.
Corlieve Therapeutics was founded in 2019.
Corlieve Therapeutics is headquartered in France.
Corlieve Therapeutics operates in the following industries: Biotechnology, Health Care.
Corlieve Therapeutics has approximately 1 employees.
Corlieve Therapeutics has completed 1 funding round. The latest funding stage is Seed.

Don't just browse. Track.

Signal Tracker monitors Corlieve Therapeutics and millions of companies for funding rounds, hiring surges, product changes, and 40+ signal types — so you never miss an opportunity.

See how it works

One analytics cookie (Google Analytics). Cookie Policy